balstilimab (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Cervical Cancer

Pending FDA approval for recurrent or metastatic cervical cancer with disease progression while on, or following, chemotherapy

Next:

Pharmacology

Mechanism of Action

Fully human monoclonal immunoglobulin G4 (IgG4) antibody that targets checkpoint inhibitor PD-1 (programmed death 1) and blocks its interaction with PD-L1 and PD-L2; this results in releasing the PD-1 pathway-mediated inhibition of the immune response, including antitumor immune response, thereby decreasing tumor growth

Binding of the PD-1 ligands PD-L1 and PD-L2 to the receptor found on T cells inhibits T-cell proliferation and cytokine production

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.